AOD-9604 exerts its effects primarily by mimicking the lipolytic activity of hGH without influencing insulin levels or inducing hyperglycemia. It activates the beta-3 adrenergic receptor and stimulates lipolysis, the breakdown of stored fat in adipose tissue. This receptor is significant in regulating energy expenditure and fat oxidation. Preclinical studies have demonstrated AOD-9604’s ability to reduce body fat in animal models, which has led to interest in its potential use for obesity management.
Unlike full-length hGH, AOD-9604 does not induce hyperglycemia or promote the growth of lean muscle mass, making it a safer option for targeting fat loss. Clinical trials have evaluated its safety and efficacy, showing that AOD-9604 is well-tolerated with a favorable safety profile. Its specific targeting of adipose tissue for fat reduction positions AOD-9604 as a promising candidate for therapeutic interventions aimed at managing obesity and metabolic disorders.
Brand: Cell Energix
AOD-9604
| Unit Size | 5 mg/vial amber |
| Unit Quantity | 1 Vial |
| Molecular Formula | C78H123N23O23S2 |
| Molecular Weight | 1815.1 |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe |
| Appearance | White Powder |
| Peptide Purity | >98.1% |
| Solubility | Soluble in water or 1% acetic acid |
The products offered on this website are furnished for in-vitro studies (Latin:in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
